HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles.
HBV
HIV
Immune exhaustion markers
PD-1
TNF-α
coinfection HBV/HIV
sFas
Journal
Pathogens & immunity
ISSN: 2469-2964
Titre abrégé: Pathog Immun
Pays: United States
ID NLM: 101683909
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
1
3
2019
pubmed:
1
3
2019
medline:
1
3
2019
Statut:
ppublish
Résumé
Hepatitis B virus (HBV) infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. Due to their shared routes of transmission, approximately 10% of HIV-infected patients worldwide are chronically coinfected with HBV. Additionally, liver disease has become a major cause of morbidity and mortality in HBV/HIV coinfected patients due to prolonged survival with the success of antiretroviral therapy. The relationship between immune exhaustion markers (PD-1/PD-L1) and apoptotic markers such as Fas/FasL, TGFβ1, TNF-α, and Th1/Th2 cytokines are not clearly delineated in HBV/HIV coinfection. Levels of soluble Fas/FasL, TGFβ1, TNF-α, and sPD-1/sPD-L1 as well as Th1 and Th2 cytokines were evaluated in the sera of HBV-monoinfected (n = 30) and HBV/HIV-coinfected (n = 15) patients and compared to levels in healthy controls (n = 20). HBV-monoinfected patients had significantly lower levels of the anti-inflammatory cytokine IL-4 ( HBV-infected and HBV/HIV-coinfected patients have unique apoptosis and inflammatory biomarker profiles that distinguish them from each other and healthy controls. The utilization of those unique biomarker profiles for monitoring disease progression or identifying individuals who may benefit from novel immunotherapies such as anti-PD-L1 or anti-PD-1 checkpoint inhibitors appears promising and warrants further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis B virus (HBV) infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. Due to their shared routes of transmission, approximately 10% of HIV-infected patients worldwide are chronically coinfected with HBV. Additionally, liver disease has become a major cause of morbidity and mortality in HBV/HIV coinfected patients due to prolonged survival with the success of antiretroviral therapy. The relationship between immune exhaustion markers (PD-1/PD-L1) and apoptotic markers such as Fas/FasL, TGFβ1, TNF-α, and Th1/Th2 cytokines are not clearly delineated in HBV/HIV coinfection.
METHODS
METHODS
Levels of soluble Fas/FasL, TGFβ1, TNF-α, and sPD-1/sPD-L1 as well as Th1 and Th2 cytokines were evaluated in the sera of HBV-monoinfected (n = 30) and HBV/HIV-coinfected (n = 15) patients and compared to levels in healthy controls (n = 20).
RESULTS
RESULTS
HBV-monoinfected patients had significantly lower levels of the anti-inflammatory cytokine IL-4 (
CONCLUSION
CONCLUSIONS
HBV-infected and HBV/HIV-coinfected patients have unique apoptosis and inflammatory biomarker profiles that distinguish them from each other and healthy controls. The utilization of those unique biomarker profiles for monitoring disease progression or identifying individuals who may benefit from novel immunotherapies such as anti-PD-L1 or anti-PD-1 checkpoint inhibitors appears promising and warrants further investigation.
Identifiants
pubmed: 30815625
doi: 10.20411/pai.v4i1.267
pmc: PMC6388707
mid: NIHMS1012331
doi:
Types de publication
Journal Article
Langues
eng
Pagination
39-65Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK078392
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI065256
Pays : United States
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST No conflict of interest for Enass A. Abdel-hameed, and Mrs. Susan D. Rouster. Drs. Li Yu, Meina Liang, Esther Song, Mark T. Esser are employees of Medimmune. Dr. Norah Shire is an employee of AstraZeneca. Dr. Mohamed Tarek M. Shata and Dr. Kenneth E. Sherman are associated editors of Pathogens and Immunity.
Références
Immunity. 1999 Sep;11(3):359-67
pubmed: 10514014
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527
Trends Immunol. 2001 May;22(5):265-8
pubmed: 11323285
J Exp Med. 2002 May 6;195(9):1089-101
pubmed: 11994415
J Virol. 2002 Sep;76(17):8609-20
pubmed: 12163580
J Immunol. 2002 Dec 1;169(11):6218-30
pubmed: 12444127
Lancet. 2002 Dec 14;360(9349):1921-6
pubmed: 12493258
Mech Ageing Dev. 2003 Apr;124(4):511-6
pubmed: 12714260
World J Gastroenterol. 2003 Dec;9(12):2671-5
pubmed: 14669310
Korean J Gastroenterol. 2004 Apr;43(4):246-51
pubmed: 15100488
Alcohol Alcohol. 2004 Jul-Aug;39(4):336-9
pubmed: 15208167
World J Gastroenterol. 2005 May 7;11(17):2653-5
pubmed: 15849828
Immunity. 2005 Jul;23(1):53-63
pubmed: 16039579
Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):97-106
pubmed: 16298544
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
J Immunol. 2006 Jul 1;177(1):739-47
pubmed: 16785573
Liver Int. 2006 Sep;26(7):840-5
pubmed: 16911467
Immunol Cell Biol. 2007 Jan;85(1):16-23
pubmed: 17130898
J Immunol. 2006 Dec 15;177(12):8844-50
pubmed: 17142787
J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):309-14
pubmed: 17159656
Clin Cancer Res. 2007 Mar 15;13(6):1823-30
pubmed: 17325342
Liver Int. 2007 Jun;27(5):694-9
pubmed: 17498256
Immunology. 2008 Jan;123(1):57-65
pubmed: 17764450
Mol Immunol. 2008 Feb;45(4):963-70
pubmed: 17868872
J Hepatol. 2008 Apr;48(4):548-58
pubmed: 18280607
J Viral Hepat. 2008 Jul;15(7):515-22
pubmed: 18331250
Hepatobiliary Pancreat Dis Int. 2008 Jun;7(3):288-95
pubmed: 18522884
Gastroenterology. 2008 Jun;134(7):1927-37, 1937.e1-2
pubmed: 18549878
Hepatology. 2008 Sep;48(3):759-69
pubmed: 18697210
Cytokine. 2008 Nov;44(2):256-61
pubmed: 18809335
Nature. 2009 Mar 12;458(7235):206-10
pubmed: 19078956
Results Probl Cell Differ. 2009;49:17-47
pubmed: 19132321
Cytokine. 2009 Sep;47(3):194-8
pubmed: 19625194
Gastroenterology. 2010 Feb;138(2):682-93, 693.e1-4
pubmed: 19800335
Immunol Invest. 2009;38(7):624-38
pubmed: 19811426
World J Gastroenterol. 2010 Feb 7;16(5):618-24
pubmed: 20128032
Zhonghua Gan Zang Bing Za Zhi. 2010 Sep;18(9):646-50
pubmed: 20943073
Clin Cancer Res. 2011 Apr 1;17(7):1915-23
pubmed: 21355078
PLoS One. 2011;6(9):e23621
pubmed: 21912640
Aliment Pharmacol Ther. 2011 Nov;34(10):1202-16
pubmed: 21981787
Lab Invest. 2012 Feb;92(2):295-304
pubmed: 22042085
Immunol Lett. 2012 Feb 29;142(1-2):78-82
pubmed: 22138406
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
BMC Res Notes. 2012 Jun 22;5:322
pubmed: 22726303
AIDS Res Hum Retroviruses. 2013 Apr;29(4):665-72
pubmed: 23259453
Hum Immunol. 2013 Mar;74(3):267-76
pubmed: 23261407
Mol Ther. 2013 Mar;21(3):688-95
pubmed: 23337984
Med Glas (Zenica). 2013 Feb;10(1):20-7
pubmed: 23348156
Int J Immunogenet. 2013 Dec;40(6):482-7
pubmed: 23560484
PLoS One. 2013 Jul 29;8(7):e70308
pubmed: 23922974
J Biol Chem. 2013 Oct 18;288(42):30708-19
pubmed: 24005672
J Med Virol. 2014 Jan;86(1):102-8
pubmed: 24009084
Immunobiology. 2014 Jan;219(1):64-77
pubmed: 24028839
J Exp Med. 2014 Aug 25;211(9):1905-18
pubmed: 25113973
Retrovirology. 2015 Feb 08;12:14
pubmed: 25756928
Mediators Inflamm. 2015;2015:281613
pubmed: 25873756
Arch Virol. 2015 Jul;160(7):1801-4
pubmed: 25990938
J Innate Immun. 2016;8(1):30-42
pubmed: 26067079
Cytokine. 2015 Dec;76(2):449-457
pubmed: 26163999
Immunol Res. 2016 Apr;64(2):412-23
pubmed: 26286967
Ghana Med J. 2015 Mar;49(1):2-6
pubmed: 26339077
Sci Rep. 2015 Nov 12;5:16552
pubmed: 26559755
Arch Virol. 2016 Apr;161(4):913-28
pubmed: 26780774
Inflamm Res. 2016 May;65(5):355-65
pubmed: 26856334
Lancet Oncol. 2016 Mar;17(3):299-308
pubmed: 26858122
J Hepatol. 2016 Jun;64(6):1274-82
pubmed: 26941095
Eur J Cancer. 2016 May;59:152-159
pubmed: 27039170
Clin Infect Dis. 2016 Nov 1;63(9):1160-1167
pubmed: 27506682
Cell Physiol Biochem. 2016;39(4):1433-43
pubmed: 27606894
Medicine (Baltimore). 2016 Dec;95(52):e5749
pubmed: 28033288
Scand J Immunol. 2017 Mar;85(3):175-181
pubmed: 28109025
Biochem Biophys Res Commun. 2017 May 6;486(3):858-863
pubmed: 28363866
Clin Rheumatol. 2017 Dec;36(12):2847-2852
pubmed: 28378099
Scand J Immunol. 2017 Aug;86(2):100-106
pubmed: 28513984
J Cutan Pathol. 2017 Sep;44(9):740-746
pubmed: 28569410
Sci Rep. 2017 Jun 20;7(1):3860
pubmed: 28634402
Oncoimmunology. 2017 Mar 31;6(5):e1310358
pubmed: 28638732
Adv Clin Exp Med. 2017 Jul;26(4):739-745
pubmed: 28691411
AIDS. 2017 Sep 24;31(15):2035-2052
pubmed: 28692539
Chin Med J (Engl). 2017 Aug 5;130(15):1810-1815
pubmed: 28748854
J Infect Dis. 2017 Sep 15;216(6):641-650
pubmed: 28934428
Front Immunol. 2017 Nov 02;8:1461
pubmed: 29163528
Adv Exp Med Biol. 2017;1036:19-31
pubmed: 29275462
Radiother Oncol. 2018 Oct;129(1):130-135
pubmed: 29366520
Oncoimmunology. 2017 Nov 20;7(3):e1389366
pubmed: 29399389
PLoS One. 2018 Feb 14;13(2):e0190058
pubmed: 29444087
J Immunol. 1987 Sep 15;139(6):2050-8
pubmed: 2957446
Int J Mol Med. 2018 Aug;42(2):703-712
pubmed: 29786112
Oncogene. 1995 Sep 21;11(6):1157-64
pubmed: 7566976
J Exp Med. 1997 Oct 6;186(7):1077-85
pubmed: 9314556
J Gastroenterol Hepatol. 1997 Oct;12(9-10):S223-6
pubmed: 9407341
J Immunol. 1998 Nov 1;161(9):4520-9
pubmed: 9794377